Relationship between HER2 gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment

The aim of the study was to investigate if parameters associated with human epidermal growth factor receptor type 2 ( ) status ( gene copy number, ratio or polysomy of chromosome 17) are related to various biological features potentially responsible for trastuzumab resistance (PTEN, IGF-1R, MUC4, EG...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2018-01, Vol.11, p.4525-4535
Main Authors: Adamczyk, Agnieszka, Kruczak, Anna, Harazin-Lechowska, Agnieszka, Ambicka, Aleksandra, Grela-Wojewoda, Aleksandra, Domagała-Haduch, Małgorzata, Janecka-Widła, Anna, Majchrzyk, Kaja, Cichocka, Anna, Ryś, Janusz, Niemiec, Joanna
Format: Article
Language:English
Subjects:
Adjuvant chemotherapy
Adjuvant therapy
Analysis
Anopheles
Antineoplastic agents
Breast cancer
Cancer metastasis
Cancer therapies
Cancer treatment
Care and treatment
Chemotherapy
Chromosomes
Deoxyribonucleic acid
DNA
Epidermal growth factor
Epidermal growth factors
Fluorescence
Formaldehyde
Gene amplification
Gene expression
Genes
Hybridization
Immunotherapy
Kinases
Medical research
Metastasis
Monoclonal antibodies
Mucins
Mutation
Oncology
Original Research
Patient outcomes
Patients
Protein expression
Proteins
Radiation therapy
Studies
Surgery
Systematic review
Targeted cancer therapy
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of the study was to investigate if parameters associated with human epidermal growth factor receptor type 2 ( ) status ( gene copy number, ratio or polysomy of chromosome 17) are related to various biological features potentially responsible for trastuzumab resistance (PTEN, IGF-1R, MUC4, EGFR, HER3, HER4, and mutation status of ) as well as their influence on survival of HER2-positive breast cancer patients treated with adjuvant chemotherapy and trastuzumab. The investigated group consisted of 117 patients with invasive ductal breast cancer (T≥1, N≥0, M0) with overexpression of HER2, who underwent radical surgery between 2007 and 2014. Status of ER, PR, and HER2 expression was retrieved from patients' files. gene copy number was investigated by fluorescence in situ hybridization using PathVysion HER-2 DNA Probe Kit II. Expression of PTEN, IGF-1R, MUC4, EGFR, HER3, and HER4 was assessed immunohistochemically on formalin-fixed paraffin-embedded tissue sections. mutation status was determined by qPCR analysis. Overexpression of HER2 protein (IHC 3+) and ER negativity corresponded to higher 2 copy number and ratio (.
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S166983